 |
|
Upcoming Events featuring
National CooperativeRx
|
|
|
Mid-Sized Retirement & Healthcare Plan Management Conference*
March 18-21, 2012
San Francisco, CA
Learn more
*As a sponsor of this educational event, National CooperativeRx is pleased to provide you and your benefits team with a $200 discount. This lowers your registration fee to $795 each when you register by February 23, 2012. To Register: * Register here and enter the code YNCR * Call the Conference Registrar at 800-864-2063 |
|
 |
National CooperativeRx is a not-for-profit coalition founded and owned by plan sponsors to achieve higher value prescription benefits through volume purchasing, clinical solutions, actionable data and unparalleled customer service. For your sales and marketing needs, please contact us at 866-679-9479, extension 223
|
|
|
New Adverse Events Web Site Gains Attention
As featured in The Wall Street Journal, the new web site by the company Adverse Events lists the side effects of drugs, and how many people have reported side effects. The company has taken US FDA reports and made the data easily accessible for over 4,500 drugs. The basic searches are free of charge, while in-depth reports cost $10 per month in user fees.
Today is National Wear Red Day February heart health tip of the week: For a healthy heart, women should aim to keep their protein intake to around 46g per day, and men should aim for 56g. Click Here for information regarding protein and heart health. National CooperativeRx Specialty Webinar Recording
Did you miss our webinar regarding specialty drugs and steps you can take to manage them? To watch the recording, visit our home page. The link is at the bottom right-hand side of the page.
|
|
Drug Information. Unlike previously suspected, cholesterol-lowering drugs (statins) have been proven equally effective for both men and women. Prior to research, it was thought that statins may be less effective for women. Research showed that statin therapy reduces the risk of heart attack by approximately 20% for both genders. (1/30) Full story
|
HealthDay. Pfizer is recalling 1M packets of birth control. A packaging error that put too few or too many pills, or pills that were out of order, in the packages could lead to unintended pregnancies. The pills being recalled have expiration dates between July 31, 2013 and March 31, 2014. (2/1) Full story
|
|
Kaiser Health News. A study that took place in Austria found that prescription errors were reduced by up to 60% after doctors switched from pen and paper prescriptions to electronic. Not only were the prescriptions more legible, but the computer systems displayed hints and warnings for proper dosing, allergies and drug interactions that may hurt a patient. Nearly 1/3 of hospital mistakes are drug related. (2/1) Full story
|
|
Fierce Biotech. 13 of the world's largest drug companies are teaming up with the Gates Foundation and the World Health Organization to fight 10 long-neglected tropical diseases. With $785M pledged, the goal is to eradicate the diseases by 2020. (Carroll, 1/30) Full story
|
|
Drug Information. Researchers have found that people with one of four rare mutations in their melatonin receptor are six times at greater risk for developing type 2 diabetes. Melatonin controls the release of insulin, which regulates blood sugar levels. (1/30) Full story
|
|
Time. The FDA has approved the first drug to fight advanced basal cell carcinoma (the most common type of skin cancer), and it will be available in 1-2 weeks. The capsule is Erivedge and is made by Genentech. The drug was given a fast review because there are no other approved treatments for basal cell carcinoma. (1/31) Full story
|
|
Drugs Information. The FDA has approved a drug to target a rare form of cystic fibrosis. The drug, Kalydeco, targets a defective protein responsible for the disease. The pill is shown to improve lung function and other symptoms. While not effective for people with the most common form of cystic fibrosis, a second trial will involve Kalydeco along with another experimental drug for those patients. (1/31) Full story
|
|
 |
|
